{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"21.5","upperLimit":"41.3","value":"30.8"},{"groupId":"OG001","lowerLimit":"12.1","upperLimit":"42.2","value":"25.0"}]}],"title":"Peripheral blood"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.5","upperLimit":"13.8","value":"6.6"},{"groupId":"OG001","lowerLimit":"3.1","upperLimit":"26.1","value":"11.1"}]}],"title":"Bone marrow"}],"denoms":[{"counts":[{"groupId":"OG000","value":"91"},{"groupId":"OG001","value":"36"}],"units":"Participants"}],"description":"The rate of MRD response is defined as the percentage of participants who had MRD negative status.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with ibrutinib-resistant or refractory chronic lymphocytic leukemia (CLL) in the Main and Expansion Cohorts","id":"OG000","title":"ABT-199 After Ibrutinib Therapy: Main and Expansion Cohorts"},{"description":"Participants with idelalisib-resistant or refractory chronic lymphocytic leukemia (CLL) in the Main and Expansion Cohorts","id":"OG001","title":"ABT-199 After Idelalisib Therapy: Main and Expansion Cohorts"}],"paramType":"NUMBER","populationDescription":"All participants in the Main and Expansion Cohorts who received at least one dose of venetoclax; indeterminate or missing samples were considered MRD positive for the calculation","reportingStatus":"POSTED","timeFrame":"Assessed at Week 24, Day 1; after the first Complete Response, Complete Remission with Incomplete Marrow Recovery, or Partial Response; at 12-week interval visits until two consecutive negative MRD levels were reported","title":"Percentage of Participants With Minimal Residual Disease (MRD) Negativity Status","type":"OTHER_PRE_SPECIFIED","unitOfMeasure":"percentage of participants"}